Transient impact of Rituximab in H1N1 vaccination-associated narcolepsy with severe psychiatric symptoms

Neurologist

Volumn 21, Issue 5, 2016, Pages 85-86

  Sarkanen, Tomi ^a,b   Alen, Reija ^a   Partinen, Markku ^b,c  

^a Central Finland Central Hospital   (Finland)

^b Vitalmed Research Centre   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

H1N1 vaccine; narcolepsy; pandemrix; psychosis; psychotic disorders; rituximab

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; FLUOXETINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; LAMOTRIGINE; METHYLPHENIDATE; METHYLPREDNISOLONE; MODAFINIL; NEUROLEPTIC AGENT; OREXIN A; OXYBATE SODIUM; RITUXIMAB; VENLAFAXINE; IMMUNOLOGIC FACTOR;

ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; CHILD; DAYTIME SOMNOLENCE; HUMAN; HYPNAGOGIC HALLUCINATION; HYPOTENSION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LEUKOCYTE COUNT; MALE; NARCOLEPSY; NAUSEA; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD; AGGRESSION; CHEMICALLY INDUCED; DELUSIONS; HALLUCINATIONS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PSYCHOLOGY;

AGGRESSION; CATAPLEXY; CHILD; DELUSIONS; HALLUCINATIONS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NARCOLEPSY; RITUXIMAB;

EID: 84987809939     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0000000000000099     Document Type: Article

References (8)

1. Partinen M, Kornum BR, Plazzi G, et al. Narcolepsy as an autoimmune disease: The role of H1N1 infection and vaccination. Lancet Neurol. 2014;13:600-613
2. Pizza F, Magnani M, Indrio C, et al. The hypocretin system and psychiatric disorders. Curr Psychiatry Rep. 2014;16:433
3. Szakács A, Hallböök T, Tideman P, et al. Psychiatric comorbidity and cognitive profile in children with narcolepsy with or without association to the H1N1 influenza vaccination. Sleep. 2015;38: 615-621
4. Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73:1333-1334
5. Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res. 2012;21:479-480
6. Weiner GJ. Rituximab: Mechanism of action. Semin Hematol. 2010;47:115-123
7. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150
8. Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep. 2003;26: 809-810